LPL Financial LLC cut its stake in Tekla Life Sciences Investors (NYSE:HQL – Get Rating) by 17.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 161,888 shares of the company’s stock after selling 35,029 shares during the period. LPL Financial LLC owned about 0.64% of Tekla Life Sciences Investors worth $2,300,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of HQL. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Tekla Life Sciences Investors by 20.1% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 79,672 shares of the company’s stock worth $1,318,000 after buying an additional 13,324 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Tekla Life Sciences Investors by 15.3% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 14,930 shares of the company’s stock worth $247,000 after acquiring an additional 1,982 shares during the last quarter. NewEdge Advisors LLC grew its position in Tekla Life Sciences Investors by 65.1% during the 1st quarter. NewEdge Advisors LLC now owns 24,099 shares of the company’s stock worth $398,000 after acquiring an additional 9,500 shares during the last quarter. Atria Wealth Solutions Inc. bought a new stake in Tekla Life Sciences Investors during the 1st quarter worth approximately $662,000. Finally, IHT Wealth Management LLC bought a new stake in Tekla Life Sciences Investors during the 1st quarter worth approximately $170,000. 15.95% of the stock is owned by institutional investors and hedge funds.
Tekla Life Sciences Investors Stock Performance
NYSE HQL opened at $13.80 on Monday. Tekla Life Sciences Investors has a one year low of $13.03 and a one year high of $16.33. The stock’s 50 day simple moving average is $13.87 and its 200 day simple moving average is $14.34.
Tekla Life Sciences Investors Cuts Dividend
About Tekla Life Sciences Investors
Tekla Life Sciences Investors operates as a closed-end investment fund, which engages in the investment in the life sciences industry. It invests in biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals and healthcare information technology and services. The company was founded on February 20, 1992 and is headquartered in Boston, MA.
- Get a free copy of the StockNews.com research report on Tekla Life Sciences Investors (HQL)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Tekla Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tekla Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.